Indianapolis – October 19, 2026 -- Half of pediatric ulcerative colitis (UC) patients who responded to Eli Lilly's Omvoh (mirikizumab-mrkz) were in clinical remission at Week 52, meeting the primary endpoint of the Phase 3 SHINE-2 study. Lilly (NYSE: LLY) says Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC, and it plans to submit the data to global regulators for a potential label expansion.

Barcelona – October 18, 2026 -- Young adults who received antibiotics from childhood onward had 1.5 times the odds of irritable bowel syndrome (IBS) at age 24 (95% CI 1.0–2.2), according to a study presented at UEG Week 2026.

Study tracks 2,853 Swedish participants from age 9–11

Researchers analysed data from 2,853 participants in the Swedish BAMSE birth cohort. Antibiotic prescriptions came from the Swedish Prescribed Drug Register, covering 2005, when participants were aged 9–11, until one year before IBS was assessed at age 24.

Barcelona – October 18, 2026 -- United European Gastroenterology (UEG) has launched a Patient Representatives Advisory Board (PRAB) at UEG Week 2026, giving patient groups a formal channel into its public affairs activities across Europe.

PRAB builds on the 2025 Digestive Health Roundtable Manifesto

The board follows UEG's Digestive Health Roundtable 2025 and its Manifesto, which called for patients to be recognised as co-creators of digestive health policy, research and care.

North Chicago – October 17, 2026 -- AbbVie (NYSE: ABBV) is presenting 20 new scientific abstracts from its inflammatory bowel disease (IBD) portfolio at the 2026 United European Gastroenterology (UEG) Week, held October 17-20 in Barcelona, Spain. The data cover long-term and real-world outcomes for Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn's disease (CD) and ulcerative colitis (UC).

Indianapolis – October 15, 2026 -- More than one in four ulcerative colitis (UC) patients (27.7%) treated with Eli Lilly and Company's Omvoh (mirikizumab-mrkz) achieved comprehensive disease control at one year, compared with 14% on placebo, according to a post hoc analysis of the LUCENT-2 trial.

In the VIVID-1 Crohn's disease trial, 20.4% of Omvoh-treated patients reached corticosteroid-free deep remission, versus 2% on placebo. Lilly will present both analyses at United European Gastroenterology (UEG) Week 2026.

New York and Suzhou, China – September 20, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).

Suzhou – – September 16, 2026 -- Accro Bioscience said AC-101 tablets have been included in the National Medical Products Administration's Center for Drug Evaluation (CDE) "Caring Plan-Extension" pilot program, targeting Blau syndrome as the proposed indication, with the public notice period closing September 11, 2026.